458 related articles for article (PubMed ID: 35385089)
61. Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children.
Yu W; Wang Y; Wu D; Liu Q; Xu L; Zhang X; Liu K; Huang X
Sci China Life Sci; 2019 Jan; 62(1):104-111. PubMed ID: 29869037
[TBL] [Abstract][Full Text] [Related]
62. Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation.
Kim T; Choi Y; Lee JH; Park S; Ahn JS; Moon JH; Shin HJ; Lee WS; Kim D; Lee HS
Korean J Intern Med; 2020 Mar; 35(2):429-437. PubMed ID: 30616303
[TBL] [Abstract][Full Text] [Related]
63. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
[TBL] [Abstract][Full Text] [Related]
64. A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST.
Byrnes CP; Hastings A; Lacej I; Palanicawandar R; Olavarria E; Anand A
HLA; 2024 Jan; 103(1):e15214. PubMed ID: 37712429
[TBL] [Abstract][Full Text] [Related]
65. Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG).
Tang F; Xu Y; Chen H; Xu L; Zhang X; Wang Y; Liu Q; Wu D; Huang X
Sci China Life Sci; 2020 Apr; 63(4):571-581. PubMed ID: 31420852
[TBL] [Abstract][Full Text] [Related]
66. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
67. Immune Modulation Properties of Zoledronic Acid on TcRγδ T-Lymphocytes After TcRαβ/CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia.
Merli P; Algeri M; Galaverna F; Milano GM; Bertaina V; Biagini S; Girolami E; Palumbo G; Sinibaldi M; Becilli M; Leone G; Boccieri E; Grapulin L; Gaspari S; Airoldi I; Strocchio L; Pagliara D; Locatelli F
Front Immunol; 2020; 11():699. PubMed ID: 32477328
[TBL] [Abstract][Full Text] [Related]
68. Myeloablative Haploidentical Donor Hematopoietic Transplantation Using Post-Transplantation Cyclophosphamide and Antithymocyte Globulin.
El Fakih R; Nassani M; Rasheed W; Hanbali A; Almohareb F; Chaudhri N; Alsharif F; Alfraih F; Shaheen M; Alhayli S; Alkhaldi H; Alshaibani A; Alotaibi AS; Alahmari A; Alamer A; Tarig A; Youniss R; Albabtain AA; Alfayez M; Saad A; Ahmed SO; Alzahrani H; Aljurf M
Transplant Cell Ther; 2024 Mar; 30(3):312.e1-312.e7. PubMed ID: 38185379
[TBL] [Abstract][Full Text] [Related]
69. [Optimization of ATG dose in haploid hematopoietic stem cell transplantation for hematologic malignancies].
Zhou X; Lu X; Tang L; Yan H; Chen WL; Shi W; Zhong ZD; You Y; Xia LH; Hu Y; Wang HF
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):557-563. PubMed ID: 32810962
[No Abstract] [Full Text] [Related]
70. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
71. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Lee KH; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Hwang HJ; Jung AR; Kim SH; Yun SC; Shin HJ
Blood; 2011 Sep; 118(9):2609-17. PubMed ID: 21715313
[TBL] [Abstract][Full Text] [Related]
72. Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria.
Knaus HA; Rottner T; Baumann CK; Cserna J; Mitterbauer M; Schulenburg A; Rabitsch W; Wohlfarth P
Transplant Cell Ther; 2022 May; 28(5):260.e1-260.e9. PubMed ID: 35217212
[TBL] [Abstract][Full Text] [Related]
73. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
74. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.
Admiraal R; van Kesteren C; Jol-van der Zijde CM; Lankester AC; Bierings MB; Egberts TC; van Tol MJ; Knibbe CA; Bredius RG; Boelens JJ
Lancet Haematol; 2015 May; 2(5):e194-203. PubMed ID: 26688094
[TBL] [Abstract][Full Text] [Related]
75. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin.
Dong L; Wu T; Zhang MJ; Gao ZY; Lu DP
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1515-24. PubMed ID: 18022582
[TBL] [Abstract][Full Text] [Related]
76. Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation.
Yan CH; Xu LP; Wang FR; Chen H; Han W; Wang Y; Wang JZ; Liu KY; Huang XJ
Bone Marrow Transplant; 2016 Mar; 51(3):391-7. PubMed ID: 26691421
[TBL] [Abstract][Full Text] [Related]
77. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
[TBL] [Abstract][Full Text] [Related]
78. Cord Haploidentical Non-In Vitro T Cell Depletion Allogeneic Hematopoietic Stem Cell Transplantation Reduces Relapse of Refractory Acute Leukemia.
Wang J; Wang Z; Wei W; Zhang W; Zhang T; Cheng H; Fei X; Yin Y; Gu J; Yuan L
Biol Blood Marrow Transplant; 2019 Jan; 25(1):121-128. PubMed ID: 30205230
[TBL] [Abstract][Full Text] [Related]
79. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
80. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.
Koreth J; Kim HT; Nikiforow S; Milford EL; Armand P; Cutler C; Glotzbecker B; Ho VT; Antin JH; Soiffer RJ; Ritz J; Alyea EP
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1516-21. PubMed ID: 24907627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]